Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study

Diabetes Research and Clinical Practice

Volumn 110, Issue 3, 2015, Pages 285-290

  Yang, Szu Pang ^a   Muo, Chih Hsin ^b,c   Wang, I Kuan ^c,d   Chang, Yen Jung ^e   Lai, Shih Wei ^b,c   Lee, Cynthia Wei Sheng ^b,c   Morisky, Donald E ^f  

^a Yang's ENT Clinic   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cohort analysis; Morphine; Type 2 diabetes mellitus

Indexed keywords

AROMATASE INHIBITOR; MEGESTROL ACETATE; MORPHINE; NEUROLEPTIC AGENT; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TAIWAN; TIME; YOUNG ADULT; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; RISK FACTOR;

ADULT; AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MEGESTROL ACETATE; MIDDLE AGED; MORPHINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TAMOXIFEN; YOUNG ADULT;

EID: 84955214483     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.10.005     Document Type: Article

References (32)

1. Portenoy R.K. Treatment of cancer pain. Lancet 2011, 377:2236-2247.
2. Gordon D.B., Dahl J.L., Miaskowski C., McCarberg B., Todd K.H., Paice J.A., et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005, 165:1574-1580.
3. Quigley C. Opioids in people with cancer-related pain. Clin Evid 2008, 2008.
4. Koyyalagunta D., Bruera E., Solanki D.R., Nouri K.H., Burton A.W., Toro M.P., et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Phys 2012, 15:ES39-ES58.
5. Wiffen P.J., McQuay H.J. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007, CD003868.
6. Flemming K. The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Sympt Manage 2010, 39:139-154.
7. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Phys 2007, 10:357-366.
8. Lee C.W., Muo C.H., Liang J.A., Sung F.C., Kao C.H. Subdural haemorrhage is associated with recent morphine treatment in patients with cancer: a retrospective population-based nested case-control study. Brain Injury 2014, 28:1353-1357.
9. Lee C.W., Muo C.H., Liang J.A., Sung F.C., Kao C.H., Yeh J.J. Pulmonary embolism is associated with current morphine treatment in patients with deep vein thrombosis. Clin Respir J 2014, 9:233-237.
10. Lee C.W., Muo C.H., Liang J.A., Sung F.C., Kao C.H. Modest increase in risk of acute coronary syndrome associated with morphine use in cancer patients: a population-based nested case-control study. Eur J Oncol Nurs: Off J Eur Oncol Nurs Soc 2014, 18:295-298.
11. Lee C.W., Muo C.H., Liang J.A., Sung F.C., Kao C.H. Association of intensive morphine treatment and increased stroke incidence in prostate cancer patients: a population-based nested case-control study. Jpn J Clin Oncol 2013, 43:776-781.
12. Pfeiffer A., Herz A. Endocrine actions of opioids. Horm Metab Res 1984, 16:386-397.
13. Cooper O.B., Brown T.T., Dobs A.S. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003, 37(Suppl. 2):S132-S136.
14. Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care 1984, 7:92-98.
15. Passariello N., Giugliano D., Ceriello A., Chiariello A., Sgambato S., D'Onofrio F. Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest 1986, 9:353-357.
16. Reece A.S. Manifold implications of forgotten hyperglycemia in clinical opiate dependence. Drug Chem Toxicol 2013, 36:55-66.
17. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373-383.
18. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
19. Powell T.M., Bagnell M.E. Your survival guide to using time-dependent covariates 2012, http://support.sas.com/resources/papers/proceedings12/168-2012.pdf.
20. Feldberg W., Shaligram S.V. The hyperglycaemic effect of morphine. Br J Pharmacol 1972, 46:602-618.
21. Ipp E., Schusdziarra V., Harris V., Unger R.H. Morphine-induced hyperglycemia: role of insulin and glucagon. Endocrinology 1980, 107:461-463.
22. Ceriello A., Giugliano D., Dello Russo P., Sgambato S., D'Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for a hyperglycaemic effect of morphine. Diabetologia 1982, 22:379.
23. Ceriello A., Dello Russo P., Curcio F., Petringa D., D'Ippolito S., Varriale M. Morphine, diabetes, and lipid metabolism. Arch Intern Med 1983, 143:1070.
24. Li L., Setoguchi S., Cabral H., Jick S. Opioids and risk of type 2 diabetes in adults with non-cancer pain. Pain Phys 2013, 16:77-88.
25. Finch P.M., Roberts L.J., Price L., Hadlow N.C., Pullan P.T. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000, 16:251-254.
26. De Maddalena C., Bellini M., Berra M., Meriggiola M.C., Aloisi A.M. Opioid-induced hypogonadism: why and how to treat it. Pain Phys 2012, 15:ES111-ES118.
27. Betancourt-Albrecht M., Cunningham G.R. Hypogonadism and diabetes. Int J Impot Res 2003, 15(Suppl. 4):S14-S20.
28. Kim J.H., Cho H.T., Kim Y.J. The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. Endocr J 2014, 61:1055-1067. [Review].
29. Heideman W.H., Middelkoop B.J., Nierkens V., Stronks K., Verhoeff A.P., van Esch S.C., et al. Changing the odds. What do we learn from prevention studies targeted at people with a positive family history of type 2 diabetes?. Prim Care Diabetes 2011, 5:215-221.
30. Slomko H., Heo H.J., Einstein F.H. Minireview: Epigenetics of obesity and diabetes in humans. Endocrinology 2012, 153:1025-1030.
31. Seely E.W., Ecker J. Clinical practice. Chronic hypertension in pregnancy. N Engl J Med 2011, 365:439-446.
32. Sedeek M., Montezano A.C., Hebert R.L., Gray S.P., Di Marco E., Jha J.C., et al. Oxidative stress, Nox isoforms and complications of diabetes - potential targets for novel therapies. J Cardiovasc Transl Res 2012, 5:509-518.